Med anledning bolagets delårsrapport för tredje kvartalet, bjuder Hamlet BioPharma in till en livesänd digital investerarträff fredagen den 24 maj klockan 12.00. Bolaget kommer att…
Read More
Hamlet BioPharma – the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections – has successfully completed the first…
Hamlet BioPharma – the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide…
Hamlet BioPharma – the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the commercial collaborations…
Immune responses in patients treated with Alpha1H – results published in the journal Cancer Medicine
Hamlet BioPharma announced on January 25 that clinical data showed a strong immune response with anti-tumor potential in Alpha1H-treated patients with bladder cancer. The submitted…
Hamlet BioPharma invites you to a series of events aiming to provide insights into the project portfolio’s strong development pipeline, the advanced technologies and the…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, participated in Økonomisk Ugebrev’s Life Science Investor Konference held in…
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, is proud to announce its participation in the Swiss Nordic…
DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,…